ReviewNew microbes and new infections2026
Comprehensive analysis of epidemiological and clinical features of Oropouche virus infection (1975 to 2025): a systematic review.
Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oropouche virus (OROV) has re-emerged since late 2023 with expanding urban transmission in Latin America. OROV causes an acute febrile illness with symptoms overlapping other arboviral infections, complicating diagnosis. Recent reports of fatalities and suspected vertical transmission have raised concerns regarding disease severity. This study aims to provide a comprehensive analysis of epidemiological and clinical features of OROV infection. Methods: We conducted a PRISMA-compliant systematic review by searching major bibliographic databases and preprint servers. Observational studies reporting OROV infection in febrile patients or the general population were included, and pooled prevalence estimates were calculated. Results: 59 studies were included. The pooled seroprevalence of anti-OROV antibodies in the general population was 7% (95% CI, 0-21%). Among febrile patients, pooled prevalence was 16% (95% CI, 10-24%) by virus detection and 24% (95% CI, 13-36%) by serology. Sex distribution was comparable (male 51% vs female 49%), while infections were most common among individuals aged 20-39 years (38%; 95% CI, 32-43%). The most frequent symptoms were fever (94%; 95% CI, 90-98%), headache (87%; 95% CI, 84-91%), and myalgia (73%; 95% CI, 67-80%), with gastrointestinal and ocular manifestations also common. Compilation of reported fatal cases showed a rapidly progressive clinical course. 17 pregnancy-associated cases suggested possible vertical transmission with heterogeneous outcomes, including congenital abnormalities and fetal loss. Conclusions: OROV contributes to acute febrile illness in Latin America and presents as a multisystem disease. Emerging reports of fatal outcomes and pregnancy-associated adverse events warrant heightened clinical awareness, improved diagnostics, and strengthened surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.